Ascentage Pharma Group International (AAPG)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Development and Sale of Novel Small-Scale Therapies	574.12M	980.65M	221.98M	209.71M	27.91M
Development and Sale of Novel Small-Scale Therapies Growth	-41.46%	341.77%	5.85%	651.38%	124.18%
Total	574.12M	980.65M	221.98M	209.71M	27.91M
Total Growth	-41.46%	341.77%	5.85%	651.38%	124.18%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Mainland China	574.12M	302.24M	221.98M	209.71M	14.97M
Mainland China Growth	89.96%	36.15%	5.85%	1301.32%	774.63%
Switzerland	-	678.42M	-	-	-
United States	-	-	-	4.00K	12.95M
United States Growth	-	-	-	-99.97%	20.54%
Total	574.12M	980.65M	221.98M	209.71M	27.91M
Total Growth	-41.46%	341.77%	5.85%	651.38%	124.18%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 19, 2026

Data Sources Report a data error